Elio Gregory Pizzutilo
Overview
Explore the profile of Elio Gregory Pizzutilo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
382
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marando A, Zagni M, Negrelli M, Valtorta E, Lauricella C, Motta V, et al.
Pathologica
. 2024 Mar;
116(1):13-21.
PMID: 38482671
The WHO Classification of Tumors, Thoracic Tumors, 5th edition, has outlined the use of TTF-1 and ΔNP63/P40 to discriminate between adenocarcinoma and squamous cell carcinoma. In 2015, the first description...
2.
Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, et al.
Clin Lung Cancer
. 2024 Jan;
25(2):190-195.
PMID: 38262770
Introduction: Despite several therapeutic efforts, lung cancer remains a highly lethal disease. Novel therapeutic approaches encompass immune-checkpoint inhibitors, targeted therapeutics and antibody-drug conjugates, with different results. Several studies have been...
3.
Pizzutilo E, Agostara A, Roazzi L, Romano R, Motta V, Lauricella C, et al.
JTO Clin Res Rep
. 2023 Dec;
4(11):100555.
PMID: 38047274
ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged...
4.
Agostara A, Roazzi L, Villa F, Romano R, Piscazzi D, Martinelli F, et al.
Expert Rev Respir Med
. 2023 Oct;
17(9):787-803.
PMID: 37817448
Introduction: Immune-checkpoint inhibitors (IO) have significantly improved outcomes of patients with non-oncogene-addicted non-small cell lung cancer (NSCLC), becoming the first-line agents for advanced disease. However, resistance remains a significant clinical...
5.
Brambilla M, Beninato T, Piemontese A, Mazzeo L, Pircher C, Manglaviti S, et al.
Clin Lung Cancer
. 2023 Sep;
24(7):631-640.e2.
PMID: 37775370
Background: Immunotherapy (IO) single agent or combined with chemotherapy (CT-IO) is the standard treatment for advanced non-small-cell lung cancer (aNSCLC) without driver alterations. IO efficacy in patients with novel driver...
6.
Patelli G, Mauri G, Tosi F, Amatu A, Bencardino K, Bonazzina E, et al.
Clin Cancer Res
. 2023 Jul;
29(22):4530-4539.
PMID: 37436743
In the evolving molecular treatment landscape of metastatic colorectal cancer (mCRC), the identification of druggable alterations is pivotal to achieve the best therapeutic opportunity for each patient. Because the number...
7.
Pizzutilo E, Romano R, Roazzi L, Agostara A, Oresti S, Zeppellini A, et al.
Cancer Res
. 2023 May;
83(14):2283-2296.
PMID: 37205627
Cancer immunotherapy, largely represented by immune checkpoint inhibitors (ICI), has led to substantial changes in preclinical cancer research and clinical oncology practice over the past decade. However, the efficacy and...
8.
Viscardi G, Vitiello F, Servetto A, Gristina V, Pizzutilo E, Canciello M, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497292
Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage non-small cell lung cancer (NSCLC) remains dismal for common relapses after curative surgery, considerable efforts are...
9.
Vaghi C, Mauri G, Agostara A, Patelli G, Pizzutilo E, Nakamura Y, et al.
Cancer Treat Rev
. 2022 Nov;
112:102488.
PMID: 36410093
ERBB2 amplification is a driver oncogenic alteration in many cancers and it has recently been incorporated among therapeutically actionable biomarkers also in metastatic colorectal cancer (mCRC). In contrast, the role...
10.
Sartore-Bianchi A, Agostara A, Patelli G, Mauri G, Pizzutilo E, Siena S
Dig Liver Dis
. 2022 Jun;
54(10):1291-1303.
PMID: 35701319
Cancer treatment is increasingly focused on targeting molecular alterations identified across different tumor histologies. While some oncogenic drivers such as microsatellite instability (MSI) and NTRK fusions are actionable with the...